Logo image
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: A study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors
Journal article   Peer reviewed

Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: A study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors

Roberto Petrioli, Alessandra Pascucci, Edoardo Francini, Stefania Marsili, Anna Ida Fiaschi, Serenella Civitelli, Gabriello Tanzini, Sandra Battistelli, Marco Lorenzi, Franco Roviello, …
Anti-cancer drugs, Vol.19(1), pp.91-96
01/2008
DOI: 10.1097/CAD.0b013e3282f21363
PMID: 18043134

View Online

Abstract

The aim of this study was to investigate the safety profile of continuous oral capecitabine at fixed dose in patients older than 75 years, having metastatic colorectal and gastric cancer. Capecitabine was administered at a fixed dose of 2000 mg daily without interruptions. Thirty-four patients were considered evaluable for toxicity and efficacy. The median age was 81 years (range 76–85). The median duration of treatment was 113 days (range 24–238 days). No grade 4 toxicity was observed. One patient had grade 3 nausea and vomiting, and one had grade 3 diarrhea. Partial responses were observed in six patients with colorectal cancer, and in one patient with gastric cancer. This study suggests that continuous oral capecitabine at a fixed daily dose of 2000 mg is well tolerated, and that it allows for the simplification and ease of dosing in elderly patients with metastatic colorectal and gastric cancer.
Capecitabine Colon cancer Elderly Gastric cancer Rectal cancer

Details

Metrics

Logo image